data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

Rezolute

(NASDAQ:RZLT)

Intraday

$2.53

-0.07[-2.69%]

After-Hours

$2.53

0[0.00%]

Perks Buy Compare Brokers

$2.53

-0.07[-2.69%]

At close: Apr 26

$2.53

0[0.00%]

After Hours: 7:46PM EDT

Overview News Earnings Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest News for Rezolute Stock (NASDAQ:RZLT)

Rezolute Stock (NASDAQ: RZLT)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Tuesday, April 23, 2024

12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights - 3 days ago
Phase 2 RIZE Study Sub-Analyses To Be Presented At 2024 Pediatric Endocrine Society Annual Meeting
Benzinga Newsdesk - 3 days ago

Friday, April 19, 2024

JMP Securities Reiterates Market Outperform on Rezolute, Maintains $7 Price Target
Benzinga Newsdesk - Apr 19, 2024, 12:28PM

Thursday, April 18, 2024

JMP Securities Reiterates Market Outperform on Rezolute, Maintains $7 Price Target
Benzinga Newsdesk - Apr 18, 2024, 1:34PM
JonesTrading Initiates Coverage On Rezolute with Buy Rating, Announces Price Target of $10
Benzinga Newsdesk - Apr 18, 2024, 8:10AM

Tuesday, April 09, 2024

Maxim Group Initiates Coverage On Rezolute with Buy Rating, Announces Price Target of $8
Benzinga Newsdesk - Apr 9, 2024, 11:35AM

Monday, April 01, 2024

CommScope Holding And 2 Other Stocks Under $3 Insiders Are Buying
Avi Kapoor - Apr 1, 2024, 7:16AM

Wednesday, March 20, 2024

$17M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
Avi Kapoor - Mar 20, 2024, 6:58AM

Monday, March 11, 2024

$1.5M Bet On This Penny Stock? Check Out These 4 Stocks Under $5 Insiders Are Aggressively Buying
Avi Kapoor - Mar 11, 2024, 2:46PM

Thursday, March 07, 2024

HC Wainwright & Co. Reiterates Buy on Rezolute, Maintains $14 Price Target
Benzinga Newsdesk - Mar 7, 2024, 7:31AM

Wednesday, March 06, 2024

Rezolute Announced Results From Preclinical Pharmacology Study That Validate The Potential For Its Lead Clinical Compound, RZ358, To Treat Individuals With Non-Islet Cell Tumors That Have Uncontrolled Hypoglycemia
Benzinga Newsdesk - Mar 6, 2024, 7:38AM

Wednesday, February 28, 2024

Lumen Technologies And 3 Other Stocks Under $3 Insiders Are Buying
Avi Kapoor - Feb 28, 2024, 7:21AM

Thursday, February 22, 2024

Charles & Colvard And 3 Other Stocks Under $2 Insiders Are Buying
Avi Kapoor - Feb 22, 2024, 8:51AM

Wednesday, February 21, 2024

Rezolute And 3 Other Penny Stocks Insiders Are Buying
Avi Kapoor - Feb 21, 2024, 8:26AM

Wednesday, February 14, 2024

HC Wainwright & Co. Reiterates Buy on Rezolute, Maintains $14 Price Target
Benzinga Newsdesk - Feb 14, 2024, 6:20AM

Tuesday, February 13, 2024

Rezolute Q2 EPS $(0.27) Beats $(0.30) Estimate
Happy Mohamed - Feb 13, 2024, 4:43PM

Wednesday, January 24, 2024

Rezolute Expands Leadership Team With Appointment Of Daron Evans, MS, MBA, As Chief Financial Officer
Benzinga Newsdesk - Jan 24, 2024, 8:15AM

Tuesday, January 23, 2024

Rezolute Receives Innovation Passport Designation From The U.K. Innovative Licensing And Access Pathway Steering Group For RZ358 In The Treatment Of Hypoglycemia Due To Congenital Hyperinsulinism
Benzinga Newsdesk - Jan 23, 2024, 8:17AM

Wednesday, December 20, 2023

Why Aclarion Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket
Avi Kapoor - Dec 20, 2023, 8:30AM

Thursday, December 14, 2023

Rezolute Has Initiated sunRIZE Phase 3 Study Of RZ358 In Patients With Congenital Hyperinsulinism; The First Clinical Site Has Now Been Activated Outside US; Additional Sites Are Being Activated Over The Coming Weeks And Into The Beginning Of 2024
Benzinga Newsdesk - Dec 14, 2023, 8:10AM

Wednesday, December 13, 2023

Rezolute Announces Completion Of Enrollment Of Its RZ402 Phase 2 Study In Diabetic Macular Edema
Benzinga Newsdesk - Dec 13, 2023, 8:05AM

Tuesday, November 14, 2023

Analyst Expectations for Rezolute's Future
Benzinga Insights - Nov 14, 2023, 1:00PM
JMP Securities Maintains Market Outperform on Rezolute, Lowers Price Target to $7
Benzinga Newsdesk - Nov 14, 2023, 11:31AM

Monday, November 13, 2023

Rezolute Q1 EPS $(0.28), Inline
Benzinga Newsdesk - Nov 13, 2023, 5:32PM
Rezolute Q1 Net Loss $14.5M; Cash, Cash Equivalents And Investment sIn Marketable Debt Securities Totaled $106.9M As Of Sept. 30
Benzinga Newsdesk - Nov 13, 2023, 5:29PM

Tuesday, October 17, 2023

The European Medicines Agency Has Granted Priority Medicines (PRIME) Eligibility To Rezolute's Rz358 For The Treatment Of Congenital Hyperinsulinism
Benzinga Newsdesk - Oct 17, 2023, 8:01AM

Wednesday, October 04, 2023

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Oct 4, 2023, 12:01PM

Monday, October 02, 2023

Stocks That Hit 52-Week Lows On Monday
Benzinga Insights - Oct 2, 2023, 1:00PM

Tuesday, September 19, 2023

Cantor Fitzgerald Reiterates Overweight on Rezolute, Maintains $5 Price Target
Benzinga Newsdesk - Sep 19, 2023, 9:11AM

Monday, September 18, 2023

Expert Ratings for Rezolute
Benzinga Insights - Sep 18, 2023, 1:00PM
HC Wainwright & Co. Reiterates Buy on Rezolute, Maintains $14 Price Target
Benzinga Newsdesk - Sep 18, 2023, 6:47AM

Friday, September 15, 2023

12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights - Sep 15, 2023, 9:06AM
JMP Securities Reiterates Market Outperform on Rezolute, Maintains $8 Price Target
Benzinga Newsdesk - Sep 15, 2023, 8:30AM

Thursday, September 14, 2023

Rezolute Q4 EPS $(0.25) Beats $(0.36) Estimate
Benzinga Newsdesk - Sep 14, 2023, 4:12PM

Friday, September 08, 2023

12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights - Sep 8, 2023, 9:06AM

Friday, July 07, 2023

Rezolute And 2 Other Penny Stocks Insiders Are Aggressively Buying
Lisa Levin - Jul 7, 2023, 8:59AM

Wednesday, June 28, 2023

What 4 Analyst Ratings Have To Say About Rezolute
Benzinga Insights - Jun 28, 2023, 12:01PM
Cantor Fitzgerald Maintains Overweight on Rezolute, Lowers Price Target to $5
Benzinga Newsdesk - Jun 28, 2023, 10:41AM
HC Wainwright & Co. Reiterates Buy on Rezolute, Maintains $14 Price Target
Benzinga Newsdesk - Jun 28, 2023, 6:14AM

Tuesday, June 27, 2023

Rezolute To Initiate A Pivotal Phase 3 Study Of RZ358 in Participants 3 Months Of Age And Older With Congenital Hyperinsulinism
Happy Mohamed - Jun 27, 2023, 4:07PM

Friday, May 19, 2023

Canaccord Genuity Maintains Buy on Rezolute, Lowers Price Target to $17
Benzinga Newsdesk - May 19, 2023, 7:56AM

Monday, May 15, 2023

HC Wainwright & Co. Maintains Buy on Rezolute, Lowers Price Target to $14
Benzinga Newsdesk - May 15, 2023, 7:17AM

Tuesday, March 28, 2023

HC Wainwright & Co. Reiterates Buy on Rezolute, Maintains $17 Price Target
Benzinga Newsdesk - Mar 28, 2023, 6:35AM

Tuesday, February 14, 2023

HC Wainwright & Co. Maintains Buy on Rezolute, Lowers Price Target to $17
Benzinga Newsdesk - Feb 14, 2023, 6:15AM

Monday, February 13, 2023

JMP Securities Reiterates Market Outperform on Rezolute, Maintains $8 Price Target
Benzinga Newsdesk - Feb 13, 2023, 8:08AM

Friday, February 10, 2023

Rezolute Q2 EPS $(0.26) Beats $(0.32) Estimate
Michael Horton - Feb 10, 2023, 4:05PM

Monday, December 19, 2022

Stocks That Hit 52-Week Lows On Monday
Benzinga Insights - Dec 19, 2022, 12:40PM

Friday, December 16, 2022

12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights - Dec 16, 2022, 8:07AM

Thursday, December 15, 2022

Rezolute Announces Initiation Of A Phase 2 Study Of RZ402 In Patients With Diabetic Macular Edema
Bill Haddad - Dec 15, 2022, 7:15AM

Wednesday, November 09, 2022

Rezolute Q1 EPS $(0.19) Up From $(0.92) YoY
Bill Haddad - Nov 9, 2022, 4:51PM

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved